T1	PROC 44 65	Ensayo clínico fase 2
T2	CHEM 70 79	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 82 91	nivolumab
#2	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 96 106	ipilimumab
#3	AnnotatorNotes T4	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	DISO 110 125	cáncer de colon
#4	AnnotatorNotes T5	C0007102; Malignant tumor of colon; Neoplastic Process
T6	PROC 174 195	Ensayo clínico fase 2
T7	CHEM 200 209	nivolumab
#5	AnnotatorNotes T7	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	CHEM 212 221	nivolumab
#6	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 226 236	ipilimumab
#7	AnnotatorNotes T9	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	DISO 240 255	cáncer de colon
#8	AnnotatorNotes T10	C0007102; Malignant tumor of colon; Neoplastic Process
T11	DISO 260 296	alta inestabilidad de microsatélites
#9	AnnotatorNotes T11	C1512430; High-Frequency Microsatellite Instability; Cell or Molecular Dysfunction
T12	DISO 506 509	CRC
T13	DISO 562 580	enfermedad medible
#10	AnnotatorNotes T13	C1513041; Measurable Disease; Disease or Syndrome
T14	DISO 298 303	MSI H
T15	PROC 590 592	RM
#11	AnnotatorNotes T15	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T16	PROC 657 679	pruebas de laboratorio
#12	AnnotatorNotes T16	C0022885; Laboratory Procedures; Laboratory Procedure
T17	DISO 614 617	MSI
T18	DISO 372 375	MSI
T19	PROC 782 795	instrucciones
#13	AnnotatorNotes T19	C0220931; Training; Educational Activity
T20	PROC 802 825	métodos anticonceptivos
#14	AnnotatorNotes T20	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T21	DISO 385 403	Cancer colorrectal
#15	AnnotatorNotes T21	C0009402; Colorectal Carcinoma; Neoplastic Process | C0346629; Malignant neoplasm of large intestine; Neoplastic Process | C1319315; Adenocarcinoma of large intestine; Neoplastic Process (?) | C4722085; Malignant neoplasm of colon and/or rectum; Neoplastic Process
T22	PROC 878 889	tratamiento
#16	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 1059 1095	Consentimiento informado por escrito
#17	AnnotatorNotes T23	C0811741; Obtain informed written consent; Health Care Activity
T24	PROC 1143 1157	procedimientos
#18	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T25	DISO 1216 1237	metástasis cerebrales
#19	AnnotatorNotes T25	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T26	DISO 1252 1277	metástasis leptomeníngeas
#20	AnnotatorNotes T26	C1704231; Metastatic Malignant Neoplasm to the Leptomeninges; Neoplastic Process
T27	PROC 1279 1290	Tratamiento
#21	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	CHEM 1305 1325	anticuerpo anti PD 1
T29	CHEM 1327 1337	anti PD L1
T30	CHEM 1339 1349	anti PD L2
T31	CHEM 1380 1390	anticuerpo
#22	AnnotatorNotes T31	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	CHEM 1393 1508	fármaco dirigido específicamente a las vías de coestimulación de los linfocitos T o el punto de control inmunitario
#23	AnnotatorNotes T32	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?) | C4684977; Immune Checkpoint Inhibitors; Pharmacologic Substance (?)
T33	ANAT 1462 1474	linfocitos T
#24	AnnotatorNotes T33	C0039194; T-Lymphocyte; Cell
T34	CHEM 1351 1362	anti CTLA 4
T35	DISO 1510 1527	Neoplasia maligna
#25	AnnotatorNotes T35	C0006826; Malignant Neoplasms; Neoplastic Process
T36	DISO 1579 1587	cánceres
#26	AnnotatorNotes T36	C0006826; Malignant Neoplasms; Neoplastic Process
T37	DISO 1620 1646	enfermedad autoinmunitaria
#27	AnnotatorNotes T37	C0004364; Autoimmune Diseases; Disease or Syndrome
T38	ANAT 360 371	colorrectal
#28	AnnotatorNotes T38	C0391908; colon rectal; Body Part, Organ, or Organ Component | C0391908; Colon and rectum; Body Part, Organ, or Organ Component | C1711309; Colorectal Region; Body Location or Region
T39	PROC 1713 1755	tratamiento sistémico con corticosteroides
T40	CHEM 1739 1755	corticosteroides
#29	AnnotatorNotes T40	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T41	CHEM 1768 1778	prednisona
#30	AnnotatorNotes T41	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T42	CHEM 1809 1838	medicamentos inmunosupresores
T43	CHEM 1893 1900	fármaco
#31	AnnotatorNotes T43	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T44	ANAT 392 403	colorrectal
#32	AnnotatorNotes T44	C0391908; colon rectal; Body Part, Organ, or Organ Component | C0391908; Colon and rectum; Body Part, Organ, or Organ Component | C1711309; Colorectal Region; Body Location or Region
T45	ANAT 120 125	colon
#33	AnnotatorNotes T45	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T46	DISO 140 151	metastásico
#34	AnnotatorNotes T46	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T47	ANAT 250 255	colon
#35	AnnotatorNotes T47	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T48	PROC 594 601	Testing
T49	DISO 319 330	metastásico
#36	AnnotatorNotes T49	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T50	PROC 585 587	TC
#37	AnnotatorNotes T50	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T51	DISO 404 407	MSI
T52	DISO 353 371	Cancer colorrectal
#38	AnnotatorNotes T52	C0009402; Colorectal Carcinoma; Neoplastic Process | C0346629; Malignant neoplasm of large intestine; Neoplastic Process | C1319315; Adenocarcinoma of large intestine; Neoplastic Process (?) | C4722085; Malignant neoplasm of colon and/or rectum; Neoplastic Process
T53	ANAT 1227 1237	cerebrales
#39	AnnotatorNotes T53	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T54	ANAT 1263 1277	leptomeníngeas
#40	AnnotatorNotes T54	C0228126; Leptomeninges; Body Part, Organ, or Organ Component | C1284563; Entire leptomeninges; Body Part, Organ, or Organ Component
T55	PROC 1874 1900	administración del fármaco
#41	AnnotatorNotes T55	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T56	Date 12 16	2013
T57	Neg_cue 408 416	negativo
T58	LIVB 452 459	mujeres
#42	AnnotatorNotes T58	C0043210; Woman; Population Group
T59	Age 460 472	>o = 18 años
T61	LIVB 542 549	sujetos
#43	AnnotatorNotes T61	C0681850; Study Subject; Group
T62	LIVB 713 744	mujeres potencialmente fértiles
#44	AnnotatorNotes T62	C4324275; Woman of childbearing potential; Population Group
T64	PHYS 618 634	Función orgánica
#45	AnnotatorNotes T64	C1254358; Organ or Tissue Function; Organ or Tissue Function
T65	Duration 910 920	23 semanas
T66	LIVB 938 969	mujeres potencialmente fertiles
#46	AnnotatorNotes T66	C4324275; Woman of childbearing potential; Population Group
T69	Duration 986 996	31 semanas
T72	Neg_cue 1197 1199	No
T73	Duration 1552 1570	los 3 años previos
T74	Neg_cue 1571 1578	excepto
T75	LIVB 1608 1615	Sujetos
#47	AnnotatorNotes T75	C0681850; Study Subject; Group
T76	Spec_cue 1666 1676	sospechada
T77	LIVB 1679 1686	Sujetos
#48	AnnotatorNotes T77	C0681850; Study Subject; Group
T78	Dose 1757 1764	> 10 mg
T79	Frequency 1779 1785	al día
T80	Duration 1849 1860	los 14 días
T82	LIVB 442 449	Varones
#49	AnnotatorNotes T82	C0025266; Male population group; Population Group
T60	PHYS 1440 1474	coestimulación de los linfocitos T
#50	AnnotatorNotes T60	C1622572; T cell costimulation; Cell Function
T63	PROC 473 489	Estado funcional
#51	AnnotatorNotes T63	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T67	PROC 521 537	histológicamente
#52	AnnotatorNotes T67	C0344441; Histology Procedure; Laboratory Procedure
T68	PROC 847 860	reclutamiento
#53	AnnotatorNotes T68	C0242800; Patient Recruitment; Research Activity
A1	Assertion T51 Negated
A4	Assertion T25 Negated
A5	Assertion T26 Negated
A6	Assertion T36 Negated
A7	Assertion T37 Speculated
A8	Status T27 History_of
A9	Status T28 History_of
A10	Status T29 History_of
A11	Status T30 History_of
A12	Status T34 History_of
A13	Status T32 History_of
A14	Status T31 History_of
A15	Status T35 History_of
A16	Status T37 History_of
A17	Status T36 History_of
#54	AnnotatorNotes T1	C0282460; Phase 2 Clinical Trials; Research Activity
#55	AnnotatorNotes T6	C0282460; Phase 2 Clinical Trials; Research Activity
#56	AnnotatorNotes T14	C1512430; High-Frequency Microsatellite Instability; Cell or Molecular Dysfunction
#57	AnnotatorNotes T39	C4053960; Systemic Corticosteroid Therapy; Therapeutic or Preventive Procedure 
#58	AnnotatorNotes T42	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#59	AnnotatorNotes T18	C1512430; High-Frequency Microsatellite Instability; Cell or Molecular Dysfunction
#60	AnnotatorNotes T51	C1512430; High-Frequency Microsatellite Instability; Cell or Molecular Dysfunction
#61	AnnotatorNotes T17	C1512430; High-Frequency Microsatellite Instability; Cell or Molecular Dysfunction
#62	AnnotatorNotes T12	C0009402; Colorectal Carcinoma; Neoplastic Process | C0346629; Malignant neoplasm of large intestine; Neoplastic Process | C1319315; Adenocarcinoma of large intestine; Neoplastic Process (?) | C4722085; Malignant neoplasm of colon and/or rectum; Neoplastic Process
#63	AnnotatorNotes T48	C0796369; microsatellite instability diagnostic test; Diagnostic Procedure | C1881824; Microsatellite instability analysis; Diagnostic Procedure
T70	Spec_cue 946 960	potencialmente
T71	Quantifier_or_Qualifier 961 969	fertiles
A18	Assertion T71 Speculated
T81	Spec_cue 721 735	potencialmente
T83	Quantifier_or_Qualifier 736 744	fértiles
A19	Assertion T83 Speculated
T84	Spec_cue 1033 1047	potencialmente
T85	Quantifier_or_Qualifier 1048 1056	fértiles
A20	Assertion T85 Speculated
T86	Observation 1011 1030	sexualmente activas
#64	AnnotatorNotes T86	C0241028; Sexually active; Finding
R1	Speculation Arg1:T81 Arg2:T83	
R2	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T83	
R3	Speculation Arg1:T70 Arg2:T71	
R4	Has_Quantifier_or_Qualifier Arg1:T66 Arg2:T71	
R5	Speculation Arg1:T84 Arg2:T85	
R6	Negation Arg1:T72 Arg2:T25	
R7	Negation Arg1:T72 Arg2:T26	
R8	Negation Arg1:T74 Arg2:T36	
T87	Quantifier_or_Qualifier 1588 1607	curables localmente
A21	Assertion T87 Negated
R9	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T87	
R10	Speculation Arg1:T76 Arg2:T37	
R11	Combined_with Arg1:T3 Arg2:T4	
R12	Location_of Arg1:T45 Arg2:T5	
R13	Before Arg1:T5 Arg2:T46	
R14	Location_of Arg1:T47 Arg2:T10	
R15	Overlap Arg1:T10 Arg2:T11	
R16	Overlap Arg1:T10 Arg2:T14	
R17	Before Arg1:T10 Arg2:T49	
T88	Observation 126 137	recidivante
#65	AnnotatorNotes T88	C2825055; Recurrence (disease attribute); Pathologic Function
R18	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T88	
T89	Observation 305 316	recidivante
#66	AnnotatorNotes T89	C2825055; Recurrence (disease attribute); Pathologic Function
R19	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T89	
R20	Overlap Arg1:T11 Arg2:T89	
R21	Overlap Arg1:T11 Arg2:T49	
R22	Overlap Arg1:T14 Arg2:T89	
R23	Overlap Arg1:T14 Arg2:T49	
R24	Combined_with Arg1:T8 Arg2:T9	
R25	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T52	
R26	Overlap Arg1:T52 Arg2:T18	
R27	Location_of Arg1:T44 Arg2:T21	
R28	Overlap Arg1:T21 Arg2:T51	
R29	Negation Arg1:T57 Arg2:T51	
T90	Result_or_Value 376 384	positivo
#67	AnnotatorNotes T90	C1446409; Positive; Finding
R30	Has_Result_or_Value Arg1:T18 Arg2:T90	
R31	Has_Age Arg1:T82 Arg2:T59	
R32	Has_Age Arg1:T58 Arg2:T59	
T91	Result_or_Value 502 505	0 1
T92	CONC 494 498	ECOG
#68	AnnotatorNotes T92	C1520224; ECOG performance status; Intellectual Product
R33	Used_for Arg1:T92 Arg2:T63	
R34	Has_Result_or_Value Arg1:T92 Arg2:T91	
R36	Experiences Arg1:T61 Arg2:T13	
R39	Experiences Arg1:T61 Arg2:T50	
R40	Experiences Arg1:T61 Arg2:T15	
T93	Observation 618 643	Función orgánica adecuada
T94	ANAT 626 634	orgánica
#69	AnnotatorNotes T94	C0178784; Organ; Body Part, Organ, or Organ Component | C1280836; Entire body organ; Body Part, Organ, or Organ Component
R44	Location_of Arg1:T94 Arg2:T64	
R45	Location_of Arg1:T94 Arg2:T93	
T95	Observation 751 767	estar de acuerdo
#70	AnnotatorNotes T95	C0600109; Willing; Finding (?)
R46	Overlap Arg1:T95 Arg2:T19	
R47	Overlap Arg1:T95 Arg2:T20	
R48	Before Arg1:T68 Arg2:T20	
R49	Overlap Arg1:T20 Arg2:T22	
R50	Has_Duration_or_Interval Arg1:T20 Arg2:T65	
R51	Experiences Arg1:T62 Arg2:T20	
R52	Experiences Arg1:T62 Arg2:T22	
R53	Experiences Arg1:T66 Arg2:T68	
R54	Has_Duration_or_Interval Arg1:T20 Arg2:T69	
T96	LIVB 1033 1056;938 945	potencialmente fértiles mujeres
#71	AnnotatorNotes T96	C4324275; Woman of childbearing potential; Population Group
R55	Has_Quantifier_or_Qualifier Arg1:T96 Arg2:T86	
R56	Experiences Arg1:T96 Arg2:T20	
R57	Experiences Arg1:T96 Arg2:T22	
R58	Experiences Arg1:T66 Arg2:T22	
T97	Observation 1104 1109	Deseo
#72	AnnotatorNotes T97	C0600109; Willing; Finding (?)
R59	Overlap Arg1:T97 Arg2:T24	
T98	Observation 1112 1121	capacidad
#73	AnnotatorNotes T98	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R60	Overlap Arg1:T98 Arg2:T24	
R61	Location_of Arg1:T53 Arg2:T25	
R62	Location_of Arg1:T54 Arg2:T26	
T99	Quantifier_or_Qualifier 1238 1245	activas
#74	AnnotatorNotes T99	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R63	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T99	
A2	Assertion T99 Negated
R64	Negation Arg1:T72 Arg2:T99	
R65	Used_for Arg1:T28 Arg2:T27	
R66	Used_for Arg1:T29 Arg2:T27	
R67	Used_for Arg1:T30 Arg2:T27	
R68	Used_for Arg1:T34 Arg2:T27	
R69	Used_for Arg1:T31 Arg2:T27	
R70	Used_for Arg1:T32 Arg2:T27	
#75	AnnotatorNotes T28	C4289970; Anti-PD1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#76	AnnotatorNotes T29	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#77	AnnotatorNotes T34	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T100	Quantifier_or_Qualifier 1528 1534	activa
A3	Status T100 History_of
#78	AnnotatorNotes T100	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R72	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T100	
R73	Overlap Arg1:T35 Arg2:T73	
R74	Negation Arg1:T74 Arg2:T87	
R75	Experiences Arg1:T75 Arg2:T37	
T101	Quantifier_or_Qualifier 1647 1653	activa
#79	AnnotatorNotes T101	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R76	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T101	
R77	Experiences Arg1:T77 Arg2:T39	
R78	Used_for Arg1:T40 Arg2:T39	
R79	Has_Dose_or_Strength Arg1:T40 Arg2:T78	
R80	Has_Dose_or_Strength Arg1:T41 Arg2:T78	
R81	Used_for Arg1:T41 Arg2:T39	
R82	Has_Frequency Arg1:T41 Arg2:T79	
T102	CONC 1768 1778;1788 1799	prednisona equivalente
R83	Has_Frequency Arg1:T40 Arg2:T79	
R84	Overlap Arg1:T42 Arg2:T80	
R85	Experiences Arg1:T77 Arg2:T42	
R86	Experiences Arg1:T77 Arg2:T55	
R87	Before Arg1:T42 Arg2:T55	
R88	Used_for Arg1:T43 Arg2:T55	
R35	Experiences Arg1:T62 Arg2:T68	
R37	Experiences Arg1:T66 Arg2:T20	
R38	Experiences Arg1:T96 Arg2:T68	
A22	Experiencer T82 Patient
A23	Experiencer T58 Patient
A24	Experiencer T66 Patient
A25	Experiencer T96 Patient
A26	Experiencer T75 Patient
A27	Experiencer T77 Patient
A28	Experiencer T61 Patient
A29	Experiencer T62 Patient
T103	Result_or_Value 408 416	negativo
R41	Has_Result_or_Value Arg1:T51 Arg2:T103	
